SEC Form 4 · accession 0001209191-18-022991
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher D Alafi
Director
Period of report
Mar 30, 2018
Accepted (ET)
Apr 3, 2018 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 30, 2018 | A | 688 | $21.05 | A | 746,155 | D | |
| Common StockF1 | holding | — | — | — | 3,953,270 | I | Held by Alafi Capital Company, LLC | |
| Common StockF2 | holding | — | — | — | 503,753 | I | Held as Trustee of The Moshe H. Alafi and Margaret E. Alafi Generation-Skipping Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Dr. Alafi is a managing partner of Alafi Capital Company, LLC and may be deemed to beneficially own the shares held by Alafi Capital Company, LLC. Dr. Alafi disclaims beneficial ownership of the securities held by Alafi Capital Company, LLC except to the extent of his pecuniary interest therein.
- F2Dr. Alafi is the Trustee of The Moshe H. Alafi and Margaret E. Alafi Generation-Skipping Trust. Dr. Alafi disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein, if any.